SBIR/STTR Research Award

Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models

Award identifier 9d5059d861ecc1e0eb255271907ef1fed78ee06e27189f56246bbe185f0e3a6cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BASE PAIR BIOTECHNOLOGIES INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
FFAKKLCKBNN7
Solicitation number
Not reported
Topic code
NIAID

Research abstract

This goal of this program is to address the limited availability of reagentsantibodiesproteinsligandsfor the identification and discrimination of immune cells and the characterization of immune responses in nonmammalian models and mammalian models for which immunologic reagents are limitede gguinea pigferretcotton ratFor examplethe progression of disease that follows infection of guinea pigs with Mycobacterium tuberculosis displays many features of human TBWhile this model has been used for more thanyears as a research tool to understand and describe disease mechanismsimmunologic analyses are constrained by the limited availability of immunological reagents specific for the guinea pigAnother example is the ferret model where immunologic studies also have been limited by the lack of immunological reagentsIn this projectBase Pair Biotechnologies will use its patented process for highly multiplexed aptamer selection to rapidly generate at leastnew affinity reagents in Phase I to important immune markers in guinea pigs and ferretsOur expert consultant in TB animal models will aid in target selection along with our staff with extensive bioinformatics experienceThese new reagents will be characterized for their binding constantsspecificityand demonstrated in ELISA like assaysand ELISpotIn Phase IIwe will use the same process to generate at leastmore reagents and employed in additional applications relevant to cancer immunology studies and clinical trials

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

15 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $6,350,488. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.